WS #16001
In healthcare, Regeneron received a positive EMA opinion for an alternative dosing schedule for its cancer drug Libtayo, which could expand its market reach. Additionally, Fractyl Health reported positive Phase 2 data for its REMAIN-1 study in obesity, showing high retention of GLP-1 induced weight loss. These developments provide specific catalysts for biotech and healthcare investors, contrasting with the broader macro uncertainty.
Healthcare and Biotech Developments
In healthcare, Regeneron received a positive EMA opinion for an alternative dosing schedule for its cancer drug Libtayo, which could expand its market reach. Additionally, Fractyl Health reported positive Phase 2 data for its REMAIN-1 study in obesity, showing high retention of GLP-1 induced weight loss. These developments provide specific catalysts for biotech and healthcare investors, contrasting with the broader macro uncertainty.